• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by iRadimed Corporation (Amendment)

    2/13/24 4:25:25 PM ET
    $IRMD
    Medical/Dental Instruments
    Health Care
    Get the next $IRMD alert in real time by email
    SC 13G/A 1 sc13g-a.htm SCHEDULE 13G/A



    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    SCHEDULE 13G
    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     
    Iradimed Corporation
    (Name of Issuer)
     
    Common Stock
    (Title of Class of Securities)
     
    46266A109
    (CUSIP Number)
     
     December 31, 2023
    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)
    ☐ Rule 13d-1(c)
    ☒ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     



     
    Page 2 of 10

    SCHEDULE 13G/A
    CUSIP No.
    46266A109
       

    1
    NAMES OF REPORTING PERSONS
     
     
     
    Roger E. Susi
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    United States of America
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
     
    162,950(1)
     
     
     
     
    6
    SHARED VOTING POWER
     
     
     
    4,425,000(2)
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     
    162,950(1)
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     
    4,425,000(2)
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
    4,587,950(3)
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     
    36.4%(4)
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     IN
     
     
     
     
     

    (1)
    Represents 162,950 shares of common stock (the “RT Shares”), par value $0.0001 per share (“Common Stock”), of Iradimed Corporation (the “Issuer”) held by the Roger E. Susi Revocable Trust (“RT”). Roger Susi is the settlor and trustee of RT.

    (2)
    Represents 2,062,500 shares of Common Stock (the “MT Shares”) held by the Matthew Susi 2008 Dynasty Trust (“MT”) and 2,362,500 shares of Common Stock (the “PT Shares”) held by the Phillip Susi 2008 Dynasty Trust (“PT”).  Roger Susi is the settlor for each of MT and PT, which are irrevocable, but for which Roger Susi holds rights as the settlor to substitute the assets of MT and PT in certain circumstances. J. Richard Susi, the brother of Roger Susi, is the trustee for each of MT and PT.

    (3)
    Represents (i) the RT Shares plus (ii) the MT Shares plus (iii) the PT Shares.

    (4)
    This percentage is calculated based upon 12,605,577 shares of Common Stock outstanding of the Issuer as of October 31, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on November 3, 2023 (the “Form 10-Q”).



    Page 3 of 10

    SCHEDULE 13G/A
    CUSIP No.
    46266A109
       

    1
    NAMES OF REPORTING PERSONS
     
     
     
    Roger E. Susi Revocable Trust
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    Florida
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
     
    162,950(1)
     
     
     
     
    6
    SHARED VOTING POWER
     
     
     
    0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     
    162,950(1)
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     
    0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
    162,950(1)
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    1.3%(2)
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
     

    (1)
    Represents the RT Shares. Roger Susi is the settlor and trustee of RT.

    (2)
    This percentage is calculated based upon 12,605,577 shares of Common Stock outstanding of the Issuer as of October 31, 2023, as reported in the Form 10-Q.



    Page 4 of 10

    SCHEDULE 13G/A
    CUSIP No.
    46266A109
       

    1
    NAMES OF REPORTING PERSONS
     
     
     
    Matthew Susi 2008 Dynasty Trust
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    Florida
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
     
    2,062,500(1)
     
     
     
     
    6
    SHARED VOTING POWER
     
     
     
    0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     
    2,062,500(1)
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     
    0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
     2,062,500(1)
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     
    16.4%(2)
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    (1)
    Represents the MT Shares.  Roger Susi is the settlor of MT, which is irrevocable, but for which Roger Susi holds rights as the settlor to substitute the assets of MT in certain circumstances. J. Richard Susi, the brother of Roger Susi, is the trustee of MT.

    (2)
    This percentage is calculated based upon 12,605,577 shares of Common Stock outstanding of the Issuer as of October 31, 2023, as reported in the Form 10-Q.



    Page 5 of 10

    SCHEDULE 13G/A
    CUSIP No.
    46266A109
       

    1
    NAMES OF REPORTING PERSONS
     
     
     
    Phillip Susi 2008 Dynasty Trust
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    Florida
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
     
    2,362,500(1)
     
     
     
     
    6
    SHARED VOTING POWER
     
     
     
    0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     
    2,362,500(1)
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     
    0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
    2,362,500(1)
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     
    18.7%(2)
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    (1)
    Represents the PT Shares.  Roger Susi is the settlor of PT, which is irrevocable, but for which Roger Susi holds rights as the settlor to substitute the assets of PT in certain circumstances. J. Richard Susi, the brother of Roger Susi, is the trustee of PT.

    (2)
    This percentage is calculated based upon 12,605,577 shares of Common Stock outstanding of the Issuer as of October 31, 2023, as reported in the Form 10-Q.



    Page 6 of 10

    SCHEDULE 13G/A
    CUSIP No.
    46266A109
       

    1
    NAMES OF REPORTING PERSONS
     
     
     
    J. Richard Susi
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    United States of America
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
     
    4,425,000(1)
     
     
     
     
    6
    SHARED VOTING POWER
     
     
     
    0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     
    4,425,000(1)
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     
    0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
    4,425,000(1)
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     
    35.1%(2)
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     
     
    (1)
    Represents (i) the MT Shares plus (ii) the PT Shares.  Roger Susi is the settlor for each of MT and PT, which are irrevocable, but for which Roger Susi holds rights as the settlor to substitute the assets of MT and PT in certain circumstances. J. Richard Susi, the brother of Roger Susi, is the trustee for each of MT and PT. J. Richard Susi disclaims any pecuniary interest in the MT Shares and the PT Shares.

    (2)
    This percentage is calculated based upon 12,605,577 shares of Common Stock outstanding of the Issuer as of October 31, 2023, as reported in the Form 10-Q.



    Page 7 of 10

    Item 1(a). Name of Issuer:

    Iradimed Corporation
     
    Item 1(b). Address of Issuer's Principal Executive Offices:

    1025 Willa Springs Dr.
    Winter Springs, Florida 32708

    Item 2(a). Name of Person Filing:

    The names of the persons filing this report (each a “Reporting Person”, collectively, the “Reporting Persons”) are:

           (i) Roger E. Susi
           (ii) Roger E. Susi Revocable Trust (“RT”)
           (iii) Matthew Susi 2008 Dynasty Trust (“MT”)
           (iv) Phillip Susi 2008 Dynasty Trust (“PT”)
           (v) J. Richard Susi

    Item 2(b). Address of Principal Business Office or, if none, Residence:

    Each Reporting Person’s address is c/o Iradimed Corporation, 1025 Willa Springs Drive, Winter Springs, Florida 32708
     
    Item 2(c).
    Citizenship:

    Each of Messrs. Roger E. Susi and J. Richard Susi is a citizen of the United States of America.
    RT is a Florida trust.
    MT is a Florida trust.
    PT is a Florida trust.
     
    Item 2(d). Title of Class of Securities:

    Common Stock, par value $0.0001 per share
     
    Item 2(e). CUSIP Number:

    46266A109




    Page 8 of 10

    Item 3.
    If this Statement is Filed Pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

    Not Applicable.

    Item 4.
    Ownership.

    The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page, including the related footnotes, for each Reporting Person and is incorporated herein by reference for such Reporting Person.

    Item 5.
    Ownership of Five Percent or Less of a Class.

    Not Applicable.

    Item 6.
    Ownership of More Than Five Percent on Behalf of Another Person.

    Not Applicable.

    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

    Not Applicable.

    Item 8.
    Identification and Classification of Members of the Group.

    Not Applicable.

    Item 9.
    Notice of Dissolution of Group.

    Not Applicable.
     
    Item 10.
    Certification.

    Not Applicable.
     

     





    Page 9 of 10

    Signature
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Dated: February 13, 2024



    /s/ Roger Susi
    Roger Susi


    ROGER E. SUSI REVOCABLE TRUST


    /s/ Roger Susi
    Roger Susi, Trustee


    MATTHEW SUSI 2008 DYNASTY TRUST


    /s/ J. Richard Susi
    J. Richard Susi, Trustee


    PHILLIP SUSI 2008 DYNASTY TRUST


    /s/ J. Richard Susi
    J. Richard Susi, Trustee



    /s/ J. Richard Susi
    J. Richard Susi
     
     

     


    Page 10 of 10


    EXHIBIT A

    Agreement of Joint Filing

    The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock of Iradimed Corporation shall be filed on behalf of each of the undersigned in accordance with Rule 13d-1(k)(1) and that this Agreement shall be filed as an exhibit to such Schedule 13G.

     
    Dated: February 13, 2024



    /s/ Roger Susi
    Roger Susi


    ROGER E. SUSI REVOCABLE TRUST


    /s/ Roger Susi
    Roger Susi, Trustee


    MATTHEW SUSI 2008 DYNASTY TRUST


    /s/ J. Richard Susi
    J. Richard Susi, Trustee


    PHILLIP SUSI 2008 DYNASTY TRUST


    /s/ J. Richard Susi
    J. Richard Susi, Trustee



    /s/ J. Richard Susi
    J. Richard Susi



    Get the next $IRMD alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $IRMD

    DatePrice TargetRatingAnalyst
    4/12/2023$50.00Buy
    Lake Street
    More analyst ratings

    $IRMD
    SEC Filings

    See more
    • iRadimed Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - IRADIMED CORP (0001325618) (Filer)

      6/23/25 9:49:42 AM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • iRadimed Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - IRADIMED CORP (0001325618) (Filer)

      5/29/25 4:15:13 PM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by iRadimed Corporation

      10-Q - IRADIMED CORP (0001325618) (Filer)

      5/5/25 4:30:33 PM ET
      $IRMD
      Medical/Dental Instruments
      Health Care

    $IRMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • IRADIMED CORPORATION Announces FDA 510(k) Clearance for MRidium® 3870 Infusion Pump System

      WINTER SPRINGS, Fla., May 29, 2025 (GLOBE NEWSWIRE) -- Iradimed Corporation (NASDAQ:IRMD), a global leader in innovative medical devices for MRI environments, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its next-generation MRidium® 3870 IV Infusion Pump System. This advanced, MRI-compatible infusion pump extends Iradimed's unique position as the world's only supplier of non-magnetic MRI infusion pump devices, established with our first-generation device in 2005. The MRidium® 3870 is poised to strengthen Iradimed's leadership for MRI-compatible infusion, addressing growing demands for safe and reliable fluid delivery in diagnostic imagi

      5/29/25 8:30:00 AM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • IRADIMED CORPORATION Announces First Quarter 2025 Financial Results

      Announces Regular Quarterly Cash Dividend of $0.17 Per Share Reaffirms Full Year 2025 Revenue and Earnings Guidance Reports record revenue of $19.5 million for the first quarter of 2025, an increase of $1.9 million or 11%, compared to the same period in 2024.Reports GAAP diluted EPS of $0.37 and non-GAAP diluted EPS of $0.42 for the first quarter of 2025, which are increases of 16% and 17%, respectively, compared to the same period in 2024.Declares a regular quarterly cash dividend of $0.17 per common share for the second quarter of 2025, payable on May 30, 2025. WINTER SPRINGS, Fla., May 05, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) announced today its

      5/5/25 7:00:00 AM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • CORRECTION -- IRADIMED CORPORATION to Hold First Quarter of 2025 Financial Results Conference Call on May 5, 2025

      WINTER SPRINGS, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by IRADIMED CORPORATION (NASDAQ:IRMD), please note that in the first paragraph the date of the earnings call should read "Monday, May 5, 2025" instead of "Friday, May 5, 2025".  The corrected release follows: IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2025 first quarter financial results before the market opens on Monday, May 5, 2025. Iradimed management will host a conference call the same day beginning at 9:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conferen

      4/28/25 9:53:08 AM ET
      $IRMD
      Medical/Dental Instruments
      Health Care

    $IRMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on iRadimed with a new price target

      Lake Street initiated coverage of iRadimed with a rating of Buy and set a new price target of $50.00

      4/12/23 9:17:10 AM ET
      $IRMD
      Medical/Dental Instruments
      Health Care

    $IRMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by iRadimed Corporation

      SC 13G/A - IRADIMED CORP (0001325618) (Subject)

      11/14/24 3:35:27 PM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by iRadimed Corporation (Amendment)

      SC 13G/A - IRADIMED CORP (0001325618) (Subject)

      2/13/24 4:25:25 PM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by iRadimed Corporation (Amendment)

      SC 13G/A - IRADIMED CORP (0001325618) (Subject)

      2/12/24 12:03:30 PM ET
      $IRMD
      Medical/Dental Instruments
      Health Care

    $IRMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF FINANCIAL OFFICER Glenn John converted options into 5,796 shares and covered exercise/tax liability with 1,412 shares, increasing direct ownership by 50% to 13,151 units (SEC Form 4)

      4 - IRADIMED CORP (0001325618) (Issuer)

      6/23/25 8:00:21 PM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form 4 filed by CHIEF FINANCIAL OFFICER Glenn John

      4/A - IRADIMED CORP (0001325618) (Issuer)

      4/7/25 4:10:04 PM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • Amendment: Director Hawkins James B converted options into 1,196 shares, increasing direct ownership by 4% to 33,545 units (SEC Form 4)

      4/A - IRADIMED CORP (0001325618) (Issuer)

      4/4/25 4:45:06 PM ET
      $IRMD
      Medical/Dental Instruments
      Health Care

    $IRMD
    Leadership Updates

    Live Leadership Updates

    See more
    • IRADIMED CORPORATION Announces Appointment of Hilda Scharen-Guivel to Board of Directors

      WINTER SPRINGS, Fla., Oct. 06, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) today announced the appointment of Hilda Scharen-Guivel to the Iradimed Board of Directors, effective October 4, 2022. Following the appointment of Ms. Scharen-Guivel, the Board will comprise five directors, three of whom are independent. "We are pleased to welcome Hilda Scharen-Guivel to the Iradimed Board," said Roger Susi, President and Chief Executive Officer of the Company. "Hilda's deep experience in regulatory oversight in the medical device industry will be invaluable to Iradimed as we develop new products and grow our business to better serve patients." Ms. Scharen-Guivel,

      10/6/22 4:05:00 PM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • Perimeter Medical Imaging AI Appoints Experienced MedTech Executive, Chris Scott, as Chief Financial Officer

      Perimeter Medical Imaging AI, Inc. (TSXV:PINK)(OTC:PYNKF) (FSE:4PC) ("Perimeter" or the "Company"), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, today announced the appointment of Chris Scott as Chief Financial Officer, effective immediately. Jeremy Sobotta, Perimeter's Chief Executive Officer stated, "We are pleased to welcome Chris to the Perimeter leadership team. Chris is a collaborative leader who brings a wealth of public company experience directly relevant to Perimeter as we continue to execute on our commercial, clinical, and corporate development goals. Previously

      6/1/22 9:35:00 AM ET
      $IRMD
      Medical/Dental Instruments
      Health Care

    $IRMD
    Financials

    Live finance-specific insights

    See more
    • IRADIMED CORPORATION Announces First Quarter 2025 Financial Results

      Announces Regular Quarterly Cash Dividend of $0.17 Per Share Reaffirms Full Year 2025 Revenue and Earnings Guidance Reports record revenue of $19.5 million for the first quarter of 2025, an increase of $1.9 million or 11%, compared to the same period in 2024.Reports GAAP diluted EPS of $0.37 and non-GAAP diluted EPS of $0.42 for the first quarter of 2025, which are increases of 16% and 17%, respectively, compared to the same period in 2024.Declares a regular quarterly cash dividend of $0.17 per common share for the second quarter of 2025, payable on May 30, 2025. WINTER SPRINGS, Fla., May 05, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) announced today its

      5/5/25 7:00:00 AM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • CORRECTION -- IRADIMED CORPORATION to Hold First Quarter of 2025 Financial Results Conference Call on May 5, 2025

      WINTER SPRINGS, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by IRADIMED CORPORATION (NASDAQ:IRMD), please note that in the first paragraph the date of the earnings call should read "Monday, May 5, 2025" instead of "Friday, May 5, 2025".  The corrected release follows: IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2025 first quarter financial results before the market opens on Monday, May 5, 2025. Iradimed management will host a conference call the same day beginning at 9:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conferen

      4/28/25 9:53:08 AM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • IRADIMED CORPORATION to Hold First Quarter of 2025 Financial Results Conference Call on May 5, 2025

      WINTER SPRINGS, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2025 first quarter financial results before the market opens on Friday, May 5, 2025. Iradimed management will host a conference call the same day beginning at 9:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register-conf.media-server.com/register/BI1cddc009ba2b427a81ea445f5669adffOnce registered, a dial-in number, unique pin, and instructions will be provided to participants. The conference call will also be available real-

      4/28/25 8:30:00 AM ET
      $IRMD
      Medical/Dental Instruments
      Health Care